129 related articles for article (PubMed ID: 18081081)
1. [Adjuvants for human vaccines].
Bröker M; Beyer C
Pharm Unserer Zeit; 2008; 37(1):42-51. PubMed ID: 18081081
[No Abstract] [Full Text] [Related]
2. Aluminium adjuvants--in retrospect and prospect.
Lindblad EB
Vaccine; 2004 Sep; 22(27-28):3658-68. PubMed ID: 15315845
[TBL] [Abstract][Full Text] [Related]
3. Freund's adjuvants.
Brown EA
Rev Allergy; 1969 May; 23(5):389-400. PubMed ID: 4892576
[No Abstract] [Full Text] [Related]
4. Vaccine immunopotentiators of the future.
Schijns VE; Degen WG
Clin Pharmacol Ther; 2007 Dec; 82(6):750-5. PubMed ID: 17914440
[TBL] [Abstract][Full Text] [Related]
5. Preformulation studies--The next advance in aluminum adjuvant-containing vaccines.
Hem SL; HogenEsch H; Middaugh CR; Volkin DB
Vaccine; 2010 Jul; 28(31):4868-70. PubMed ID: 20488265
[No Abstract] [Full Text] [Related]
6. Nano- and microparticles as adjuvants in vaccine design: success and failure is related to host natural antibodies.
Sinyakov MS; Dror M; Lublin-Tennenbaum T; Salzberg S; Margel S; Avtalion RR
Vaccine; 2006 Oct; 24(42-43):6534-41. PubMed ID: 16842893
[TBL] [Abstract][Full Text] [Related]
7. How to find immunomodulators--a look backward and forward.
Sedlacek HH
Behring Inst Mitt; 1984 May; (74):122-31. PubMed ID: 6383321
[TBL] [Abstract][Full Text] [Related]
8. Stearyl tyrosine. An organic equivalent of aluminum-based immunoadjuvants.
Penney C
Pharm Biotechnol; 1995; 6():611-24. PubMed ID: 7551239
[No Abstract] [Full Text] [Related]
9. A need for effective adjuvants.
Bunce CJ; Morse MA
Curr Opin Mol Ther; 2003 Feb; 5(1):8-9. PubMed ID: 12669464
[No Abstract] [Full Text] [Related]
10. [Anaphylaxis and adjuvants].
Muranaka S
Arerugi; 2010 Jan; 59(1):61-5. PubMed ID: 20358647
[No Abstract] [Full Text] [Related]
11. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.
Hem SL; Hogenesch H
Expert Rev Vaccines; 2007 Oct; 6(5):685-98. PubMed ID: 17931150
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant formulations for experimental vaccines.
Stewart-Tull DE
Methods Mol Med; 2003; 87():175-94. PubMed ID: 12958456
[No Abstract] [Full Text] [Related]
13. Designing and building the next generation of improved vaccine adjuvants.
Brito LA; O'Hagan DT
J Control Release; 2014 Sep; 190():563-79. PubMed ID: 24998942
[TBL] [Abstract][Full Text] [Related]
14. A brush with danger: historical review of topical immunotherapy for alopecia areata.
Macbeth AE; Lee KY; Levell NJ
Clin Exp Dermatol; 2013 Dec; 38(8):960-1. PubMed ID: 23795819
[No Abstract] [Full Text] [Related]
15. Critical appraisal of emulsified oil adjuvants applied to viral vaccines.
Hilleman MR
Prog Med Virol; 1966; 8():131-82. PubMed ID: 5333821
[No Abstract] [Full Text] [Related]
16. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
Nordly P; Madsen HB; Nielsen HM; Foged C
Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
[TBL] [Abstract][Full Text] [Related]
17. [A review of the study on swainsonine--toxic elements of locoweed].
Shi Y; Li M; Xu F
Zhong Yao Cai; 1999 Jan; 22(1):47-9. PubMed ID: 12892056
[No Abstract] [Full Text] [Related]
18. Influenza A (H5N1) pandemic prototype vaccine Fluval.
Vajo Z
Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
[TBL] [Abstract][Full Text] [Related]
19. An aluminium adjuvant in a vaccine is an acute exposure to aluminium.
Exley C
J Trace Elem Med Biol; 2020 Jan; 57():57-59. PubMed ID: 31561170
[No Abstract] [Full Text] [Related]
20. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
